/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/6009876c53548812a466d17d/2021-02-03-18-30-58-545-601aebe28cb62a0458e46e84.jpg)
On September 21, the Federal Trade Commission (“FTC”) filed a suit against a private equity firm and one of its portfolio companies,...
A Fresh Take
Insights on M&A, litigation, and corporate governance in the US.
/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/5e7cb459342a4f03803cef70/2021-02-05-19-53-09-725-601da2255354890560beaf3e.jpg)
A trio of recent, high-profile M&A cases in the Delaware Court of Chancery merit special attention by M&A acquirors. In each of these...
/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/5e728ae3703aee0e148e57be/2020-05-18-23-56-38-237-5ec320b68cb62b0f1c69542a.png)
On Wednesday, August 9, 2023, President Biden issued Executive Order 14105, Addressing United States Investments in Certain National...
The U.S. Department of Justice Antitrust Division (“DOJ”) and Federal Trade Commission (“FTC”) yesterday released a draft of revised...
The recent surge in bolt-on M&A in the life sciences sector is being fueled by the use of contingent value rights. Notwithstanding...
The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of...
The Association of Corporate Counsel hosted its annual Life Sciences Conference from May 9-11, 2023, which featured presentations from a...
The Staff of SEC’s Division of Corporation Finance (the “Staff”) recently issued a series of Compliance and Disclosure Interpretations...
It’s that time again. For companies that are required to hold advisory shareholder “say-on-pay” votes on their executive compensation,...
In a rare move on February 27, 2023, the Federal Trade Commission (FTC) issued its first statement akin to a closing statement since...
Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly using deal structures designed...
For over a decade, industry watchdogs, patient groups and various lawmakers have been calling for drug pricing reform—initially with...